Italia markets closed
FTSE MIB
27.113,95 +92,91 (+0,34%) Dow Jones
33.274,15 +415,12 (+1,26%) Nasdaq
12.221,91 +208,43 (+1,74%) Nikkei 225
28.041,48 +258,55 (+0,93%) Petrolio
75,70 +1,33 (+1,79%) Bitcoin EUR
26.259,93 +500,80 (+1,94%)
Incyte Corporation (0J9P.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 06:20PM BST
| Chiusura precedente | 71,26 |
| Aperto | 71,28 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 71,28 - 72,11 |
| Intervallo di 52 settimane | 71,28 - 72,11 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 157,201M |
| Beta (5 anni mensile) | 0,74 |
| Rapporto PE (ttm) | 0,17 |
| EPS (ttm) | 4,20 |
| Prossima data utili | 01 mag 2023 - 05 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for auto
© 2023 Yahoo. Tutti i diritti riservati.
